IL128994D0 - Quinoline derivatives inhibiting the effect of growth factors such as vegf - Google Patents

Quinoline derivatives inhibiting the effect of growth factors such as vegf

Info

Publication number
IL128994D0
IL128994D0 IL12899497A IL12899497A IL128994D0 IL 128994 D0 IL128994 D0 IL 128994D0 IL 12899497 A IL12899497 A IL 12899497A IL 12899497 A IL12899497 A IL 12899497A IL 128994 D0 IL128994 D0 IL 128994D0
Authority
IL
Israel
Prior art keywords
vegf
effect
growth factors
quinoline derivatives
derivatives inhibiting
Prior art date
Application number
IL12899497A
Other versions
IL128994A (en
Original Assignee
Zeneca Ltd
Zeneca Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP96402034 priority Critical
Application filed by Zeneca Ltd, Zeneca Pharma Sa filed Critical Zeneca Ltd
Priority to PCT/GB1997/002587 priority patent/WO1998013350A1/en
Publication of IL128994D0 publication Critical patent/IL128994D0/en
Publication of IL128994A publication Critical patent/IL128994A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/233Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • C07D215/44Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
IL12899497A 1996-09-25 1997-09-23 Quinoline and naphthyridine derivatives and salts thereof, processes for their preparation, pharmaceutical compositions containing them and use thereof as medicaments IL128994A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP96402034 1996-09-25
PCT/GB1997/002587 WO1998013350A1 (en) 1996-09-25 1997-09-23 Qinoline derivatives inhibiting the effect of growth factors such as vegf

Publications (2)

Publication Number Publication Date
IL128994D0 true IL128994D0 (en) 2000-02-17
IL128994A IL128994A (en) 2004-12-15

Family

ID=8225290

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12899497A IL128994A (en) 1996-09-25 1997-09-23 Quinoline and naphthyridine derivatives and salts thereof, processes for their preparation, pharmaceutical compositions containing them and use thereof as medicaments

Country Status (13)

Country Link
US (1) US6809097B1 (en)
EP (1) EP0929526B1 (en)
JP (1) JP2001500890A (en)
KR (1) KR100567649B1 (en)
CN (1) CN1252054C (en)
AT (1) AT300521T (en)
AU (1) AU733551B2 (en)
CA (1) CA2263479A1 (en)
DE (2) DE69733825D1 (en)
IL (1) IL128994A (en)
NO (1) NO321003B1 (en)
NZ (1) NZ334125A (en)
WO (1) WO1998013350A1 (en)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997017329A1 (en) * 1995-11-07 1997-05-15 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
AT368665T (en) 1997-08-22 2007-08-15 Astrazeneca Ab Oxindolylchinazole derivatives as angiogenesehemmer
ES2291041T3 (en) * 1998-08-13 2008-02-16 Novartis Ag Method for treating ocular neovascular diseases.
AU5991699A (en) * 1998-09-21 2000-04-10 Biochem Pharma Inc. Quinolizinones as integrin inhibitors
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
SK287767B6 (en) 1998-09-29 2011-09-05 Wyeth Holdings Corporation Substituted 3-cyanoquinolines
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
PL199802B1 (en) * 1999-02-10 2008-10-31 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors
GB9904103D0 (en) 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
US6355636B1 (en) 1999-04-21 2002-03-12 American Cyanamid Company Substituted 3-cyano-[1.7],[1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases
US6548496B2 (en) 1999-04-21 2003-04-15 American Cyanamid Company Substituted 3-cyano-[1.7], [1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases
ES2216884T3 (en) * 1999-04-21 2004-11-01 Wyeth Holdings Corporation 3-cyano- (1.7), (1.5) and (1.8) naphthyridine substituted which are inhibitors of tyrosine kinases.
GB9910580D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910579D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
JP2003512353A (en) * 1999-10-19 2003-04-02 メルク エンド カムパニー インコーポレーテッド Tyrosine kinase inhibitors
AU769222B2 (en) * 1999-11-05 2004-01-22 Genzyme Corporation Quinazoline derivatives as VEGF inhibitors
US6638929B2 (en) 1999-12-29 2003-10-28 Wyeth Tricyclic protein kinase inhibitors
AU3171001A (en) * 2000-02-09 2001-08-20 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase
DE60112268T2 (en) 2000-03-06 2006-05-24 Astrazeneca Ab Using quinazolinderivate as inhibitors of angiogenesis
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
US6608048B2 (en) 2000-03-28 2003-08-19 Wyeth Holdings Tricyclic protein kinase inhibitors
AR035851A1 (en) * 2000-03-28 2004-07-21 Wyeth Corp 3-cyanoquinolines, 3-cyano-1,6-naphthyridines and 3-cyano-1,7-naphthyridines as inhibitors of protein kinases
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
IL151626D0 (en) * 2000-04-07 2003-04-10 Astrazeneca Ab Quinazoline compounds
MXPA02012943A (en) * 2000-08-09 2003-05-15 Astrazeneca Ab Cinnoline compounds.
CA2416525A1 (en) * 2000-08-09 2002-02-14 Astrazeneca Ab Indole, azaindole and indazole derivatives having vegf inhibiting activity
KR20030036686A (en) 2000-08-09 2003-05-09 아스트라제네카 아베 Quinoline derivatives having vegf inhibiting activity
AU7762101A (en) * 2000-08-09 2002-03-04 Astrazeneca Ab Antiangiogenic bicyclic derivatives
EP1313734B1 (en) 2000-09-01 2009-11-11 Novartis Vaccines and Diagnostics, Inc. Aza heterocyclic derivatives and their therapeutic use
EP1650203B1 (en) 2000-09-11 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Process of preparation of benzimidazol-2-yl quinolinone derivatives
DE60128936T2 (en) 2000-10-12 2008-04-10 Merck & Co, Inc. Aza and polyaza naphthalenyl acid acid amide as hiv integrase inhibitors
AU1152702A (en) 2000-10-12 2002-04-22 Merck & Co Inc Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
JP2004517860A (en) 2000-10-12 2004-06-17 メルク エンド カムパニー インコーポレーテッドMerck & Company Incoporated Useful aza as Hiv integrase inhibitor - and polyaza - naphthalenyl carboxamides
AT355275T (en) 2000-10-20 2006-03-15 Eisai R&D Man Co Ltd Nitrogen-containing aromatic ring compounds for the treatment of tumor diseases
JP2004514718A (en) * 2000-11-02 2004-05-20 アストラゼネカ アクチボラグ Substituted quinoline such as an anti-cancer agent
EP1337513A1 (en) 2000-11-02 2003-08-27 AstraZeneca AB 4-substituted quinolines as antitumor agents
US6603005B2 (en) 2000-11-15 2003-08-05 Aventis Pharma S.A. Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them
JP4259877B2 (en) 2000-12-11 2009-04-30 アムジエン・インコーポレーテツド CXCR3 antagonist
GB0104422D0 (en) * 2001-02-22 2001-04-11 Glaxo Group Ltd Quinoline derivative
US6602884B2 (en) 2001-03-13 2003-08-05 Aventis Pharma S.A. Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
PE00082003A1 (en) 2001-06-19 2003-01-22 Squibb Bristol Myers Co dual inhibitors of PDE 4 and PDE 7
DE60215178T2 (en) 2001-07-16 2007-08-23 Astrazeneca Ab Quinoline derivatives and their use as inhibitors of tyrosine kinase
AR036256A1 (en) 2001-08-17 2004-08-25 Merck & Co Inc sodium salt of an inhibitor of HIV integrase, processes for their preparation, pharmaceutical compositions containing them and their use for the manufacture of a medicament
US20060004437A1 (en) 2001-08-29 2006-01-05 Swaminathan Jayaraman Structurally variable stents
CA2473572C (en) 2002-02-01 2011-05-10 Astrazeneca Ab Quinazoline compounds
EP1496836B1 (en) 2002-03-15 2008-09-24 Merck & Co., Inc. N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors
ES2274268T3 (en) * 2002-05-31 2007-05-16 Bayer Pharmaceuticals Corporation Compounds and compositions for the treatment of diabetes and disorders related to diabetes.
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
CN100526312C (en) * 2002-08-23 2009-08-12 诺华疫苗和诊断公司 Benzimidazole quinolinones and uses thereof
EP2573079A3 (en) 2002-08-23 2015-03-11 Novartis AG Benzimidazole quinolinones and uses thereof
EP1548008A4 (en) * 2002-08-23 2008-08-06 Kirin Pharma Kk Compound having tgf-beta inhibitory activity and medicinal composition containing the same
GB0225579D0 (en) * 2002-11-02 2002-12-11 Astrazeneca Ab Chemical compounds
WO2004041829A1 (en) 2002-11-04 2004-05-21 Astrazeneca Ab Quinazoline derivatives as src tyrosine kinase inhibitors
US7384937B2 (en) 2002-11-06 2008-06-10 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
NZ539425A (en) 2002-11-13 2007-11-30 Chiron Corp Methods of treating cancer and related methods
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
ES2369652T3 (en) 2003-09-26 2011-12-02 Exelixis Inc. C-met modulators and methods of use.
MXPA06004194A (en) * 2003-11-07 2006-06-28 Chiron Corp Inhibition of fgfr3 and treatment of multiple myeloma.
CN100450998C (en) 2003-11-11 2009-01-14 卫材R&D管理有限公司 Urea derivative and process for producing the same
EP1699780A1 (en) * 2003-12-23 2006-09-13 Pfizer, Inc. Novel quinoline derivatives
RU2377988C2 (en) 2004-02-20 2010-01-10 Новартис Вэксинес Энд Дайэгностикс, Инк. Modulation of inflammatory and metastatic processes
EP1724268A4 (en) * 2004-02-20 2010-04-21 Kirin Pharma Kk Compound having tgf-beta inhibitory activity and pharmaceutical composition containing same
WO2005115145A2 (en) * 2004-05-20 2005-12-08 Wyeth Quinone substituted quinazoline and quinoline kinase inhibitors
ES2322175T3 (en) 2004-09-17 2009-06-17 EISAI R&D MANAGEMENT CO., LTD. Medicinal composition with improved stability and reduced gelification.
CA2603748A1 (en) * 2005-04-06 2006-10-12 Exelixis, Inc. C-met modulators and methods of use
MX2007014381A (en) 2005-05-17 2008-02-06 Novartis Ag Methods for synthesizing heterocyclic compounds.
WO2006127926A2 (en) 2005-05-23 2006-11-30 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
WO2007015578A1 (en) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
US20080293738A1 (en) 2005-11-29 2008-11-27 Novartis Ag Formulation of Quinolinones
KR20080080395A (en) * 2005-12-21 2008-09-03 아보트 러보러터리즈 Anti-viral compounds
TW200738707A (en) * 2005-12-21 2007-10-16 Abbott Lab Anti-viral compounds
EP2345652A1 (en) 2005-12-21 2011-07-20 Abbott Laboratories Antiviral compounds
RU2467007C2 (en) 2005-12-21 2012-11-20 Эбботт Лэборетриз [1,8]naphthyridine derivatives, useful as inhibitors of hcv virus replication
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
SG175599A1 (en) 2006-01-31 2011-11-28 Array Biopharma Inc Kinase inhibitors and methods of use thereof
WO2007113548A1 (en) * 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives
US7601716B2 (en) * 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
WO2007136103A1 (en) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
WO2008026748A1 (en) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
EP2094276A4 (en) 2006-12-20 2011-01-05 Abbott Lab Anti-viral compounds
WO2008093855A1 (en) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
US20080234267A1 (en) * 2007-03-20 2008-09-25 Karen Elizabeth Lackey Compounds and Methods of Treatment
CA2685888A1 (en) * 2007-05-09 2008-11-20 Pfizer Inc. Substituted heterocyclic derivatives and their pharmaceutical use and compositions
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
CN101945869B (en) 2007-12-19 2014-06-18 癌症研究技术有限公司 Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
GB0807609D0 (en) 2008-04-25 2008-06-04 Cancer Rec Tech Ltd Therapeutic compounds and their use
CN101570530B (en) 2008-04-30 2011-08-17 上海医药工业研究院 Method for preparing flavonoid dimeric compound as well as medium and preparation method thereof
SG10201510586PA (en) 2008-06-30 2016-01-28 Mesoblast Inc Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy
BRPI0914936A2 (en) * 2008-07-03 2015-10-20 Merck Patent Gmbh naphthyridininones as aurora kinase inhibitors
TW201022258A (en) * 2008-11-13 2010-06-16 Exelixis Inc Methods of preparing quinoline derivatives
JP2012511017A (en) * 2008-12-04 2012-05-17 エグゼリクシス, インコーポレイテッド Method for preparing quinoline derivatives
EA026425B1 (en) 2009-01-16 2017-04-28 Экселиксис, Инк. Malate salt of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
CN102030705B (en) 2009-09-30 2012-12-19 上海睿智化学研究有限公司 Synthesis method of 7- benzyloxy-6-methoxyl-4-hydroxyquinoline
KR101086456B1 (en) * 2009-10-15 2011-11-25 한국원자력의학원 Composition for inhibiting TGF-? comprising imidazopurine derivatives
ES2469367T3 (en) 2010-02-01 2014-06-18 Cancer Research Technology Limited 1- (5-tert-butyl-2-phenyl-2H-pyrazol-3-yl) -3- [2-fluoro-4- (1-methyl-2-oxo-2,3-dihydro-1H-imidazo [ 4,5-b] pyridin-7-yloxy) -phenyl] -urea and related compounds and their use in therapy
US20130053375A1 (en) * 2010-05-07 2013-02-28 Glaxo Group Limited Amino-quinolines as kinase inhibitors
EP2586443B1 (en) 2010-06-25 2016-03-16 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
UY33549A (en) * 2010-08-10 2012-01-31 Glaxo Group Ltd Quinolyl amines as inhibitors of kinases
JP6026441B2 (en) * 2011-03-04 2016-11-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Aminoquinolines as kinase inhibitors
CA2828946C (en) 2011-04-18 2016-06-21 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
EP3444363A1 (en) 2011-06-03 2019-02-20 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
TWI547494B (en) 2011-08-18 2016-09-01 Glaxosmithkline Ip Dev Ltd As the amine quinazoline kinase inhibitors of
AR088872A1 (en) 2011-11-14 2014-07-16 Cephalon Inc Uracil derivatives as inhibitors of kinase axl and c-met
AR092530A1 (en) 2012-09-13 2015-04-22 Glaxosmithkline Llc Amino-quinoline compound, pharmaceutical composition comprising the same and use of said compound for the preparation of a medicament
TWI592417B (en) 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 Prodrugs of amino quinazoline kinase inhibitor
CN103709162B (en) * 2012-09-29 2016-12-07 中国科学院上海药物研究所 Trisubstituted imidazo phthalazinone compound and its preparation and use
RU2015115397A (en) 2012-12-21 2017-01-25 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Amorphic chinoline derivative form and method for producing it
CN105143208B (en) 2013-02-21 2017-09-26 葛兰素史密斯克莱知识产权发展有限公司 It is used as the quinazoline of kinase inhibitor
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
AU2015309862A1 (en) 2014-08-28 2017-03-02 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
JP2018513150A (en) * 2015-04-07 2018-05-24 グアンドン・チョンシェン・ファーマスーティカル・カンパニー・リミテッド Tyrosine kinase inhibitor and pharmaceutical composition containing the same
EP3414330A4 (en) 2016-02-08 2019-07-03 Vitrisa Therapeutics Inc Compositions with improved intravitreal half-life and uses thereof
WO2017168448A1 (en) 2016-03-30 2017-10-05 Council Of Scientific & Industrial Research Silicon incorporated quinolines with anti-malarial and anti-toxoplasmosis activity
CN106831711A (en) * 2016-12-30 2017-06-13 苏州大学 Benzo[e][1,2,4]triazine-1-oxygen derivative as well as composition and application thereof
CN107115344B (en) * 2017-03-23 2019-06-14 广东众生睿创生物科技有限公司 Tyrosine kinase inhibitor is preparing the purposes in the drug for preventing and/or treating fibrotic disease

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3075981A (en) * 1958-04-03 1963-01-29 Sterling Drug Inc 1-[aromatic-(lower-alkyl)]-4-(aromaticimino)-1, 4-dihydroquinolines and their preparation
SE317376B (en) 1961-07-10 1969-11-17 Roussel Uclaf
US3272824A (en) * 1962-12-06 1966-09-13 Norwich Pharma Co 4-amino-6, 7-di(lower) alkoxyquinolines
JPS4320294Y1 (en) * 1964-10-31 1968-08-26
FR2077455A1 (en) 1969-09-03 1971-10-29 Aries Robert 5-haloveratryl-4-aminoquinoles - antimalarials amoebicides anthelmintics anticoccidials
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
US3936461A (en) * 1973-09-24 1976-02-03 Warner-Lambert Company Substituted 4-benzylquinolines
FR2498187B1 (en) * 1981-01-16 1983-09-30 Rhone Poulenc Sante
WO1986006718A1 (en) * 1985-05-17 1986-11-20 The Australian National University Antimalarial compounds
IL81307D0 (en) 1986-01-23 1987-08-31 Union Carbide Agricult Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
USRE36256E (en) 1991-05-10 1999-07-20 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5656643A (en) 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
DE69222637D1 (en) 1991-05-10 1997-11-13 Rhone Poulenc Rorer Int To mono- and bicyclic aryl and heteroaryl derivatives having an inhibitory effect on the EGF and / or PDGF receptor tyrosine kinase
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US6194439B1 (en) 1991-05-29 2001-02-27 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
JPH06504294A (en) * 1991-08-02 1994-05-19
GB9127252D0 (en) 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
US5792771A (en) 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5712395A (en) 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
IL117620D0 (en) 1995-03-27 1996-07-23 Fujisawa Pharmaceutical Co Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same
US5773459A (en) 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
US5650415A (en) 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
JPH11507052A (en) 1995-06-07 1999-06-22 スージェン・インコーポレーテッド Quinazoline and pharmaceutical compositions
TR199800012T1 (en) 1995-07-06 1998-04-21 Novartis Ag Piroloprimid days for preparation and administration.
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
WO1997017329A1 (en) * 1995-11-07 1997-05-15 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CH690773A5 (en) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo (2,3-d) pyrimide and their use.
DE69720965T2 (en) 1996-02-13 2004-02-05 Astrazeneca Ab Quinazoline derivatives and their use as inhibitors vegf
IL125954A (en) 1996-03-05 2003-06-24 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect
DE69734149T2 (en) 1996-03-15 2006-07-06 Astrazeneca Ab Cinoline derivatives and use as remedies
AU5533996A (en) 1996-04-04 1997-10-29 University Of Nebraska Board Of Regents Synthetic triple helix-forming compounds
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
AR007857A1 (en) 1996-07-13 1999-11-24 Glaxo Group Ltd fused heterocyclic compounds as inhibitors of protein tyrosine kinases, methods for their preparation, intermediates used in pharmaceutical ycomposiciones medicine containing them.
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
AT480521T (en) 1996-10-01 2010-09-15 Kyowa Hakko Kirin Co Ltd Nitrogen containing heterocyclic compounds
CN1237177A (en) 1996-11-27 1999-12-01 辉瑞大药厂 Fused bicyclic pyrimidine derivatives
CO4950519A1 (en) 1997-02-13 2000-09-01 Novartis Ag Phthalazines, pharmaceutical preparations comprising them and process for their preparation
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
ZA9802771B (en) 1997-04-03 1999-10-01 American Cyanamid Co Substituted 3-Cyano Quinolines.
AR016817A1 (en) 1997-08-14 2001-08-01 Smithkline Beecham Plc Phenylurea derivatives or phenylthiourea, process for their preparation, collection of compounds, intermediate compounds, pharmaceutical composition, method of treatment and use of said compounds for the manufacture of a medicament
AT368665T (en) 1997-08-22 2007-08-15 Astrazeneca Ab Oxindolylchinazole derivatives as angiogenesehemmer

Also Published As

Publication number Publication date
CA2263479A1 (en) 1998-04-02
KR100567649B1 (en) 2006-04-05
DE69733825T2 (en) 2006-06-08
NZ334125A (en) 2000-10-27
CN1237963A (en) 1999-12-08
AU4313797A (en) 1998-04-17
NO991423D0 (en) 1999-03-24
CN1252054C (en) 2006-04-19
NO991423L (en) 1999-05-11
US6809097B1 (en) 2004-10-26
AT300521T (en) 2005-08-15
EP0929526A1 (en) 1999-07-21
KR20000048575A (en) 2000-07-25
EP0929526B1 (en) 2005-07-27
WO1998013350A1 (en) 1998-04-02
NO321003B1 (en) 2006-02-27
DE69733825D1 (en) 2005-09-01
JP2001500890A (en) 2001-01-23
AU733551B2 (en) 2001-05-17
IL128994A (en) 2004-12-15

Similar Documents

Publication Publication Date Title
DK0754059T4 (en) Applicable methods and compositions for inhibiting angiogenesis
GB2319250B (en) Derivatives of 6,8-Difluoro-7-Hydroxycoumarin
AU656576B2 (en) Quinoline derivatives
GB2328691B (en) Inhibition of microbial growth
DE69739593D1 (en) Nitrogenic heterocycles as factor xa-hemmer
DE69739561D1 (en) Piperidine derivatives as intermediates for the preparation of paroxetines and process for their preparation
AU689664B2 (en) Methods of inhibiting conditions associated with neuropeptide
DE69935992D1 (en) Polycyclic aryl and heteroaryl substituted tertiary heteroalkylamines, for inhibiting the activity of the cholesteryl ester transfer protein
GR3031783T3 (en) 1H-indole-3-acetamide derivatives as sPLA2 inhibitors.
PL332212A1 (en) Heteroaroyl derivatives of herbicidal properties
PL191566B1 (en) Substituted 2-(2-2,6-dioxopiperidin-3-yl)phtalamides and 1-oxoisoindolins as well as method of lowering the TNF-Ó level
IL124461D0 (en) Angiogenesis inhibiting pyridazinamines
PT880502E (en) Amino-heterocyclic derivatives as antitrombotic or anticogulant agents
PL198124B1 (en) 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
HU9702036D0 (en) New heterocyclic compounds as inhibitors of leucocita-adhesion and wla-4-antagonists
PT942904E (en) 3-thiocarbamoilpirazol derivatives as pesticides
PL327735A1 (en) Novel substituted derivatives of imidazole
AU6908498A (en) Naphthyridine derivatives
IL141445D0 (en) Benzazine derivatives as phosphodiesterase 4 inhibitors
HU9700358D0 (en) New oxazolidinon derivatives
PL329276A1 (en) Substituted benzenezulphonamide derivatives as prodrugs of cox-2 inhibitors
AU5231598A (en) Triarylethanes useful as pde iv inhibitors
RU98123001A (en) Arylpyrimidine derivatives
PT891332E (en) 6-phenylpyridyl-2-amine derivatives
GR3035068T3 (en) Derivatives of benzosulphonamides as inhibitors of the enzyme cyclo-oxygenase ii

Legal Events

Date Code Title Description
FF Patents granted
KB Patents renewed
KB Patents renewed
MM9K Patent not in force due to non-payment of renewal fees